Redeye provides its initial take on MedCap’s Q2 2025 report, which roughly matched our top-line projection and beat our adjusted EBITA estimate. As expected, softening comparables and continued growth resulted in MedCap returning to y/y profit expansion this quarter. We expect the company to sustain its momentum in coming quarters.
LÄS MER
